おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Code Biotherapeutics
About
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $75M
- Industries
- Biotechnology,Health Care,Life Science
- Founded date
- Jan 1, 2020
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 7, 2022 | Series A | $75M | 1 | — | — | Detail |
| Apr 20, 2021 | Seed | $10M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
CureDuchenne Ventures
|
— | Series A |
